{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:57:40Z","timestamp":1780959460407,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite the approval of 177Lu-PSMA-617 as standard treatment for patients with mCRPC, at least 50% of patients do not respond to the therapy, especially those with visceral disease. This study analyzes real-world outcomes of 177Lu-PSMA-I&amp;T used in heavily pretreated patients in Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of patients with mCRPC previously treated with at least one androgen receptor pathway inhibitor (ARPI) who underwent 177Lu-PSMA-I&amp;T between 2020 and 2025 in two large oncology centers. Our primary endpoint was prostate-specific antigen (PSA) response rate of 50% or more (PSA50). Secondary endpoints included overall survival (OS) and time to next sequential therapies (TNST). Statistical analyses were performed in JAMOVI and RStudio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-three patients were included, with median age 74 years and median baseline PSA 41 ng\/mL. Prior to 177Lu-PSMA-I&amp;T, 86% received more than one ARPI line and 23.3% underwent more than one taxane-based chemotherapy. Visceral disease was present in 41.9%. The overall PSA50 response for all patients was 44.2% and for patients with visceral disease was 33.3%. Median OS was 13.9 months [95% confidence interval (CI) 10.9\u201319.2] and 12-month survival was 55.5% [95% CI 42.1%-73.3%]. Out of the 24 patients who received subsequent therapies, median TNST was 2.9 months [95% CI 1.6\u20135.4].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results showed that 177Lu-PSMA-I&amp;T achieved a PSA response comparable to those treated with 177Lu-PSMA-617 in randomized trials, despite our heavily treated patients\u2019 characteristics. A significant number of patients had visceral disease with expected lower PSA response, highlighting the need for more active combinations in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41824-026-00305-8","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:02:47Z","timestamp":1780956167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["177Lutetium-PSMA-I&amp;T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&amp;T in Brazil"],"prefix":"10.1186","volume":"10","author":[{"given":"Helena F.","family":"Bruzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela C. K.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah B. V.","family":"Bekierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Altino","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alexandre","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Mosci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonne S.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Palazzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Freire","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Tarouquella","family":"da Silva\u00a0Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-848X","authenticated-orcid":false,"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"11","key":"305_CR10","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","volume":"25","author":"M Abdel-Wahab","year":"2024","unstructured":"Abdel-Wahab M, Giammarile F, Carrara M et al (2024) Radiotherapy and theranostics: a Lancet Oncology Commission. Lancet Oncol 25(11):e545\u2013580. https:\/\/doi.org\/10.1016\/S1470-2045(24)00407-8","journal-title":"Lancet Oncol"},{"key":"305_CR21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I et al (2023) Single-dose [(177)Lu]Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol 24:1266\u20131276. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5","journal-title":"Lancet Oncol"},{"issue":"6","key":"305_CR9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.semnuclmed.2025.07.005","volume":"55","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Brink A et al (2025) Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. Semin Nucl Med 55(6):1032\u20131044. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.07.005","journal-title":"Semin Nucl Med"},{"issue":"3","key":"305_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0045-1807251","volume":"24","author":"A Brink","year":"2025","unstructured":"Brink A, Cerci JJ, Giammarile F et al (2025) Global challenges in the provision of theranostic services: the International Atomic Energy Agency (IAEA) perspective. World J Nucl Med 24(3):238\u2013243. https:\/\/doi.org\/10.1055\/s-0045-1807251","journal-title":"World J Nucl Med"},{"key":"305_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med 59:469\u2013478. https:\/\/doi.org\/10.2967\/jnumed.117.198119","journal-title":"J Nucl Med"},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M et al (2024) [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicenter, randomized, phase 2 trial. Lancet Oncol 25:563\u2013571. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9","journal-title":"Lancet Oncol"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR et al (2021) Nomograms to predict outcomes after [(177)Lu]Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicenter, retrospective study. Lancet Oncol 22:1115\u20131125. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6","journal-title":"Lancet Oncol"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomized, open-label, phase 2 trial. Lancet 397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","volume":"23","author":"A Iravani","year":"2020","unstructured":"Iravani A, Violet J, Azad A, Hofman MS (2020) Lutetium-177 prostate-specific membrane antigen theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis 23:38\u201352. https:\/\/doi.org\/10.1038\/s41391-019-0174-x","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Suppl 5","key":"305_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.2025.43.5_suppl.255","volume":"43","author":"C Jani","year":"2025","unstructured":"Jani C, Panian J, Govindarajan A et al (2025) Molecular evolution of homologous recombination repair gene alterations in metastatic prostate cancer: a circulating tumor DNA\u2013based study. J Clin Oncol 43(Suppl 5):255. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.255","journal-title":"J Clin Oncol"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/biomedicines13030569","volume":"13","author":"E Kalender","year":"2025","unstructured":"Kalender E, Ekinci E, Elbo\u011fa U, \u015eahin E (2025) Efficacy of [(177)Lu]Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer and liver metastases: insights into survival outcomes and predictors of response. Biomedicines 13:569. https:\/\/doi.org\/10.3390\/biomedicines13030569","journal-title":"Biomedicines"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-020-04828-5","volume":"48","author":"F Khreish","year":"2021","unstructured":"Khreish F, Kochems N, Rosar F et al (2021) Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 48:103\u2013112. https:\/\/doi.org\/10.1007\/s00259-020-04828-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","volume":"43","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Kim YI (2018) Therapeutic responses and survival effects of [(177)Lu]Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis. Clin Nucl Med 43:728\u2013734. https:\/\/doi.org\/10.1097\/RLU.0000000000002210","journal-title":"Clin Nucl Med"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00259-025-07082-9","volume":"52","author":"SW Ling","year":"2025","unstructured":"Ling SW, de Lussanet Q, Ananta M et al (2025) First real-world clinical experience with [(177)Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. Eur J Nucl Med Mol Imaging 52:2034\u20132040. https:\/\/doi.org\/10.1007\/s00259-025-07082-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Goyal S, Sternberg CN et al (2024) [(177)Lu]Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomized, controlled trial. Lancet 404:1227\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2","journal-title":"Lancet"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.2967\/jnumed.124.268277","volume":"65","author":"M Muniz","year":"2024","unstructured":"Muniz M, Sartor O, Orme JJ et al (2024) Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [(177)Lu]Lu-PSMA-617. J Nucl Med 65:1932\u20131938. https:\/\/doi.org\/10.2967\/jnumed.124.268277","journal-title":"J Nucl Med"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"oyaf358","DOI":"10.1093\/oncolo\/oyaf358","volume":"30","author":"J Panian","year":"2025","unstructured":"Panian J, Henderson NC, Herchenhorn D et al (2025) Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with [(177)Lu]Lu-PSMA-617. Oncologist 30:oyaf358. https:\/\/doi.org\/10.1093\/oncolo\/oyaf358","journal-title":"Oncologist"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","volume":"51","author":"F Rosar","year":"2024","unstructured":"Rosar F, Schuler J, Burgard C et al (2024) Efficacy and safety of rechallenge [(177)Lu]Lu-PSMA-617 radioligand therapy after initial partial remission in patients with metastatic castration-resistant prostate cancer: evaluation of a prospective registry (REALITY study). Eur J Nucl Med Mol Imaging 51:4151\u20134162. https:\/\/doi.org\/10.1007\/s00259-024-06825-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 16","key":"305_CR20","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","volume":"40","author":"S Sandhu","year":"2022","unstructured":"Sandhu S, Joshua AM, Emmett L et al (2022) PRINCE: phase I trial of [(177)Lu]Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 40(Suppl 16):5017. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5017","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"305_CR4","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L et al (2023) LuPARP: phase 1 trial of [(177)Lu]Lu-PSMA-617 and olaparib in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 41(Suppl 16):5005. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5005","journal-title":"J Clin Oncol"},{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"305_CR5","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","volume":"43","author":"S Subramaniam","year":"2025","unstructured":"Subramaniam S, Thomas H, Tan TH et al (2025) [(177)Lu]Lu-PSMA-617 with ipilimumab and nivolumab in metastatic castration-resistant prostate cancer: an investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). J Clin Oncol 43(Suppl 16):5016. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5016","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"305_CR7","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa ST, Sartor AO, Saad F et al (2023) PSM Addition: a phase 3 trial to compare treatment with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care alone in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 41(Suppl):TPS5116. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS210","journal-title":"J Clin Oncol"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00305-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:02:48Z","timestamp":1780956168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00305-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00305-8","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Instituto D\u2019Or de Pesquisa e Ensino review board (protocol number: 7.335.537) and by Plataforma Brazil (CAAE: 83791424.1.0000.5249).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is an observational study. The requirement for informed consent was waived by the institutional Instituto D`Or de Pesquisa e Ensino review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}